Literature DB >> 31898107

Infliximab Does Not Promote the Presence of Collagenolytic Bacteria in a Mouse Model of Colorectal Anastomosis.

Sara Gaines1, Sanjiv Hyoju1, Ashley J Williamson1, Jasper B van Praagh1,2, Olga Zaborina1, David T Rubin1, John C Alverdy1, Benjamin D Shogan1, Neil Hyman3.   

Abstract

BACKGROUND: Previous work from our group has suggested a pivotal role for collagenolytic bacteria in the development of anastomotic complications. Tumor necrosis factor antagonists are a mainstay of treatment for patients with inflammatory bowel disease. The reported impact of these agents on key surgical outcomes such as anastomotic leak has been inconsistent. The objective of this study is to assess the impact of infliximab on the anastomotic microbiome in a mouse model of colon resection.
DESIGN: BALB/c mice underwent colon resection with primary anastomosis. Mice were randomly assigned to receive either an intraperitoneal dose of saline (control) or 10 mg/kg of infliximab for 8 weeks prior to surgery. On postoperative day 7, the animals were sacrificed. Anastomotic tissues were analyzed by histology with TUNNEL staining as a marker of epithelial apoptosis. In order to assess compositional and functional changes of the local microbiome, anastomotic tissues were further analyzed by 16S rRNA V4 region sequencing and for the presence of collagenolytic strains that may impair anastomotic healing. The main outcome measures were microbiome community structure and the presence of collagenolytic bacteria.
RESULTS: Infliximab-treated mice demonstrated an increase in epithelial apoptosis, consistent with the expected drug effect. Although infliximab modified the perianastomotic microbiome, no increase in the presence of collagenolytic bacteria was observed.
CONCLUSIONS: Infliximab did not promote the emergence of collagenolytic bacteria or demonstrably impair anastomotic healing in a mouse model of colon resection and anastomosis.

Entities:  

Keywords:  Anastomotic leak; Infliximab; Microbiome

Mesh:

Substances:

Year:  2020        PMID: 31898107      PMCID: PMC7931774          DOI: 10.1007/s11605-019-04486-5

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  32 in total

1.  Post-operative abdominal complications in Crohn's disease in the biological era: Systematic review and meta-analysis.

Authors:  Peter Waterland; Thanos Athanasiou; Heena Patel
Journal:  World J Gastrointest Surg       Date:  2016-03-27

2.  Inflammation, Antibiotics, and Diet as Environmental Stressors of the Gut Microbiome in Pediatric Crohn's Disease.

Authors:  James D Lewis; Eric Z Chen; Robert N Baldassano; Anthony R Otley; Anne M Griffiths; Dale Lee; Kyle Bittinger; Aubrey Bailey; Elliot S Friedman; Christian Hoffmann; Lindsey Albenberg; Rohini Sinha; Charlene Compher; Erin Gilroy; Lisa Nessel; Amy Grant; Christel Chehoud; Hongzhe Li; Gary D Wu; Frederic D Bushman
Journal:  Cell Host Microbe       Date:  2015-10-14       Impact factor: 21.023

3.  Market share and costs of biologic therapies for inflammatory bowel disease in the USA.

Authors:  H Yu; D MacIsaac; J J Wong; Z M Sellers; A A Wren; R Bensen; C Kin; K T Park
Journal:  Aliment Pharmacol Ther       Date:  2017-11-22       Impact factor: 8.171

4.  Collagen degradation and MMP9 activation by Enterococcus faecalis contribute to intestinal anastomotic leak.

Authors:  Benjamin D Shogan; Natalia Belogortseva; Preston M Luong; Alexander Zaborin; Simon Lax; Cindy Bethel; Marc Ward; Joseph P Muldoon; Mark Singer; Gary An; Konstantin Umanskiy; Vani Konda; Baddr Shakhsheer; James Luo; Robin Klabbers; Lynn E Hancock; Jack Gilbert; Olga Zaborina; John C Alverdy
Journal:  Sci Transl Med       Date:  2015-05-06       Impact factor: 17.956

5.  Oral Polyphosphate Suppresses Bacterial Collagenase Production and Prevents Anastomotic Leak Due to Serratia marcescens and Pseudomonas aeruginosa.

Authors:  Sanjiv K Hyoju; Robin E Klabbers; Melissa Aaron; Monika A Krezalek; Alexander Zaborin; Mara Wiegerinck; Neil H Hyman; Olga Zaborina; Harry Van Goor; John C Alverdy
Journal:  Ann Surg       Date:  2018-06       Impact factor: 12.969

6.  Exposure to Anti-tumor Necrosis Factor Medications Increases the Incidence of Pouchitis After Restorative Proctocolectomy in Patients With Ulcerative Colitis.

Authors:  Marco Bertucci Zoccali; Neil H Hyman; Kinga B Skowron; Michele Rubin; Lisa M Cannon; Roger D Hurst; Konstantin Umanskiy; David T Rubin; Benjamin D Shogan
Journal:  Dis Colon Rectum       Date:  2019-11       Impact factor: 4.585

Review 7.  Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-analysis.

Authors:  Vincent Billioud; Alexander C Ford; Emilie Del Tedesco; Jean-Frédéric Colombel; Xavier Roblin; Laurent Peyrin-Biroulet
Journal:  J Crohns Colitis       Date:  2013-03-20       Impact factor: 9.071

Review 8.  The impact of peri-operative anti-TNF treatment on anastomosis-related complications in Crohn's disease patients. A critical review.

Authors:  Ioannis Papaconstantinou; Christos Zeglinas; Maria Gazouli; Konstantinos Nastos; Anneza Yiallourou; Apostolos Papalois; Charalambos Tzathas
Journal:  J Gastrointest Surg       Date:  2014-03-06       Impact factor: 3.452

9.  DADA2: High-resolution sample inference from Illumina amplicon data.

Authors:  Benjamin J Callahan; Paul J McMurdie; Michael J Rosen; Andrew W Han; Amy Jo A Johnson; Susan P Holmes
Journal:  Nat Methods       Date:  2016-05-23       Impact factor: 28.547

Review 10.  Surgery in the age of biologics.

Authors:  Daniel J Wong; Eve M Roth; Joseph D Feuerstein; Vitaliy Y Poylin
Journal:  Gastroenterol Rep (Oxf)       Date:  2019-03-11
View more
  1 in total

1.  Mucosa plication reinforced colorectal anastomosis and trans-anal vacuum drainage: a pilot study with preliminary results.

Authors:  Alexander Ferko; Juraj Váňa; Marek Adámik; Adam Švec; Michal Žáček; Michal Demeter; Marián Grendár
Journal:  Updates Surg       Date:  2021-06-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.